Membranes and Cancer Chemotherapy

References

• Nicolson G L, Poste G. The cancer cell: dynamic aspects and modifications in cell-surface organization. New Engl J Med 1976; 295: 197–203; 253–258
   PubMed Web of Science ®Google Scholar
• Wallach D FH. Membrane anomalies of tumor cells. Prog Exp Tumor Res 1978; 22: 1–38
   PubMedGoogle Scholar
• Holley R W, Kiernan J A. “Contact inhibition” of cell division of 3T3 cells. Proc Natl Acad Sci (USA) 1968; 60: 303–312
   Google Scholar
• Wright T C, Ukena T E, Campbell R, et al. Rates of aggregation, loss of anchorage dependence, and tumorigenkity of cultured cells. Proc Natl Acad Sci (USA) 1977; 74: 258–262
   PubMed Web of Science ®Google Scholar
• Ukena T E, Goldman E, Benjamin T L, et al. Lack of correlation between agglutinability, the surface distribution of Con A and post-confluence inhibition of cell division in ten cell lines. Cell 1976; 7: 213–222
   PubMed Web of Science ®Google Scholar
• Shin S, Freedman V H, Risser R, et al. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci (USA) 1975; 72: 4435–4439
   PubMed Web of Science ®Google Scholar
• Shields R, Pollock K. The adhesion of BHK and PyBHK cells to the substratum. Cell 1974; 3: 31–38
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor-associated glycolipid markers in experimental and human cancer. Membrane Alterations in Cancer, A Mikita, S Tsuiki, S Fujii, L Warren. Plenum Press, New York 1983; 113–127
   Google Scholar
• Anderson W B, Johnson G S, Pastan I. Transformation of chick-embryo fibroblasts by wild-type and temperature-sensitive Rous sarcoma virus alters adenylate cyclase activity. Proc Natl Acad Sci (USA) 1973; 70: 1055–1059
   PubMed Web of Science ®Google Scholar
• Unkeless J C, Tobia A, Ossowski L, et al. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med 1973; 137: 85–111
   PubMed Web of Science ®Google Scholar
• Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? GHA Clowes Memorial Lecture. Cancer Res 1986; 46: 467–473
   PubMed Web of Science ®Google Scholar
• Poutsiaka D D, Black P H. Shedding from cancer cells and its importance in determining the pathophysiology of cancer. Membrane Alterations in Cancer, A Mikita, S Tsuiki, S Fujii, L Warren. Plenum Press, New York 1983; 47–57
   Google Scholar
• Rothman J E, Lenard J. Membrane asymmetry. Science 1977; 195: 743–753
   PubMed Web of Science ®Google Scholar
• Bergelson L D, Barsukov L I. Topological asymmetry of phospholipids in membranes. Science 1977; 197: 224–230
   PubMed Web of Science ®Google Scholar
• Karnovsky M J, Kleinfeld A M, Hoover R L, et al. The concept of lipid domains in membranes. J Cell Biol 1982; 94: 1–6
   PubMed Web of Science ®Google Scholar
• Seelig J, Seelig A. Lipid conformation in model membranes and biological membranes. Q Rev Biophys 1980; 13: 19–61
   PubMed Web of Science ®Google Scholar
• Smith R L, Oldfield E. Dynamic structure of membranes by deuterium NMR. Science 1984; 225: 280–288
   PubMed Web of Science ®Google Scholar
• Weltzien H U. Cytolytic and membrane-perturbing properties of lysosphatidylcholine. Biochim Biophys Acta 1979; 559: 259–287
   PubMed Web of Science ®Google Scholar
• Munder P G, Modolell M. Adjuvant induced formation of lysophosphatides and their role in immune response. Int Arch Allergy 1973; 45: 133–135
   Web of Science ®Google Scholar
• Arnold B, Reuther R, Weltzien H U. Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim Biophys Acta 1978; 530: 45–55
   Google Scholar
• Arnold D, Weltzien H U, Westphal O. Uber die Synthese von Lysolecithinen und ihren Atheranaloga. Liebigs Ann Chem 1967; 709: 234–239
   PubMedGoogle Scholar
• Munder P G, Weltzien H U, Modolell M. Lysolecithin analogs: a new class of immunopotentiators. Immunopathology, VIIth International Symposium, P A Miescher. Schwabe and Co. Publishers, Basel 1977; 411–423
   Google Scholar
• Andreesen R, Modolell M, Weltzien H U, et al. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res 1978; 38: 3894–3899
   PubMed Web of Science ®Google Scholar
• Modolell M, Andreesen R, Pahlke W, et al. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res 1979; 39: 4681–4686
   PubMed Web of Science ®Google Scholar
• Vogler W R, Whigham E, Bennett W D, et al. Effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines. Exp Hematol 1985; 13: 629–633
   PubMed Web of Science ®Google Scholar
• Herrmann D BJ, Ferber E, Munder P G. Ether phospholipids as inhibitors of the arachidonoyl-CoA: 1-acyl-M-glycero-3-phosphocholine acyltransferase in macrophages. Biochim Biophys Acta 1986; 876: 28–35
   PubMed Web of Science ®Google Scholar
• Berdel W E, Fromm M, Fink U, et al. Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin. Cancer Res 1983; 43: 5538–5543
   PubMed Web of Science ®Google Scholar
• Morris-Natschke S, Surles J R, Daniel L W, et al. Synthesis of sulfur analogous of alkyl lysophospholipid and neoplastic cell growth inhibitory properties. J Med Chem 1986; 29: 2114–2117
   PubMed Web of Science ®Google Scholar
• Noseda A, Berens M E, Piantadosi C, et al. Neoplastic cell inhibition with new ether lipid analogs. Lipids 1987; 22: 878–883
   PubMed Web of Science ®Google Scholar
• Berdel W E, Von Hoff D D, Unger C, et al. Ether lipid derivatives antineoplastic activity in vitro and the structure-activity relationship. Lipids 1986; 21: 301–304
   PubMed Web of Science ®Google Scholar
• Hoffman D R, Hajdu J, Snyder F. Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts. Blood 1984; 63: 545–552
   PubMed Web of Science ®Google Scholar
• Houlihan W J, Lee M L, Munder P G, et al. Antitumor activity of SRI 62–834, a cyclic ether analog of ET-18-OCH3. Lipids 1987; 22: 884–890
   PubMed Web of Science ®Google Scholar
• Soodsma J F, Piantadosi C, Snyder F. The biocleavage of alkyl glyceryl ethers in Morris hepatomas and other transplantable neoplasms. Cancer Res 1970; 30: 309–311
   PubMed Web of Science ®Google Scholar
• Berdel W E, Greiner E, Fink U, et al. Cytotoxicity of alkyl-lysophosphoiipid derivatives and low-alkyl-cleavage enzyme activities in rat brain rumor cells. Cancer Res 1983; 43: 541–545
   PubMed Web of Science ®Google Scholar
• Berdel W E, Fink U, Egger B, et al. Inhibition by alkyl-lysophosopholipids of tritiated thymidine uptake in cells of human malignant urologic tumors. J Natl Cancer Inst 1981; 66: 813–817
   PubMed Web of Science ®Google Scholar
• Hoffman D R, Hoffman L H, Snyder F. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. Cancer Res 1986; 46: 5803–5809
   PubMed Web of Science ®Google Scholar
• Unger C, Eibl H, Kim D J, et al. Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities. J Natl Cancer Inst 1987; 78: 219–222
   PubMed Web of Science ®Google Scholar
• Lee T-C, Blank M L, Fitzgerald V, et al. Substrate specificity in the biocleavage of the O-alkyl bond: l-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid) and its metabolites. Arch Biochem Biophys 1981; 208: 353–357
   PubMed Web of Science ®Google Scholar
• Berdel W E, Andreesen R, Munder P G. Synthetic alkyl-phospholipid analogs: a new class of antitumor agents. Phospholipids and Cellular Regulation, J F Kuo. CRC press, Inc., Boca Raton, FL 1985; 41–73
   Google Scholar
• Fleer E AM, Unger C, Kim D J, et al. Metabolism of ether phospholipids and analogs in neoplastic cells. Lipids 1987; 22: 856–861
   PubMed Web of Science ®Google Scholar
• Kotting J, Unger C, Eibl H. Substrate specificity of 0-alkylglycerol monooxygenase (E.C. 1.14.16.5), solubilized from rat liver microsomes. Lipids 1987; 22: 831–835
   PubMed Web of Science ®Google Scholar
• Storme G A, Berdel W E, Van Blitterswijk W J, et al. Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res 1985; 45: 351–357
   PubMed Web of Science ®Google Scholar
• Long R C, Small W C, Brynes R K, et al. Effects of alkyl-lysophospholipids on human leukemic cell lines measured by nuclear magnetic resonance. Cancer Res 1983; 43: 770–775
   PubMed Web of Science ®Google Scholar
• Noseda A, White J G, Modest E J. Effects of ether lipid analogs of platelet activating factor on the physical properties of model membranes (abstr). Proc Am Assoc Cancer Res 1987; 28: 13
   Web of Science ®Google Scholar
• Berdel W E, Greiner E, Fink U, et al. Cytotoxic effects of alkyl-lysophospholipids in human brain tumor cells. Oncology 1984; 41: 140–145
   PubMed Web of Science ®Google Scholar
• Van Blitterswijk W J, Hilkmann H, Storme G A. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids 1987; 22: 820–823
   PubMed Web of Science ®Google Scholar
• Helfman D M, Barnes K C, Kinkade J M, et al. Phospholipid' sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL-60 and K562, and its inhibition by alkyl-lysophospholipid. Cancer Res 1983; 43: 2955–2961
   PubMed Web of Science ®Google Scholar
• Kiss Z, Deli E, Vogler W R, et al. Antileukemic agent alkyllysophospholipid regulates phosphorylation of distinct proteins in HL60 and K562 cells and differentiation of HL60 cells promoted by phorbol ester. Biochem Biophys Res Comm 1987; 142: 661–666
   PubMed Web of Science ®Google Scholar
• King M T, Eckhardt K, Gocke E, et al. Failure to detect mutagenic effects of anti-tumor alkyl-lysophospholipids. Cancer Lett 1981; 12: 217–222
   PubMed Web of Science ®Google Scholar
• Andreesen R, Modolell M, Oepke G HF, et al. Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids. Anticancer Res 1982; 2: 95–100
   PubMed Web of Science ®Google Scholar
• Berdel W E, Bausert W R, Weltzien H U, et al. The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer 1980; 16: 1199–1204
   PubMed Web of Science ®Google Scholar
• Berdel W E, Munder P G. Metastatic growth of 3-Lewis lung carcinoma in mice treated with alkyl-lysophospholipids and lysophospholipid-induced peritoneal macrophages. Anticancer Res 1981; 1: 397–402
   PubMed Web of Science ®Google Scholar
• Berdel W E, Fink U, Egger B, et al. Growth inhibition of malignant hypernephroma cells by autologous lysophospholipid incubated macrophages obtained by a new method. Anticancer Res 1981; 1: 135–140
   PubMed Web of Science ®Google Scholar
• Berdel W E, Fink U, Thiel E, et al. Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction. Immunobiology 1982; 163: 511–520
   Google Scholar
• Andreesen R, Osterholz J, Luckenbach G A, et al. Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J Natl Cancer Inst 1984; 72: 53–59
   PubMed Web of Science ®Google Scholar
• Munder P G, Modolell M, Bausert W, . Alkyllysophospholipids in cancer therapy. Progress in Cancer Research and Therapy, Vol 16, Augmenting Agents in Cancer Therapy, E M Hersh, M A Chirigos, M J Mastrangelo, et al. Raven Press, New York 1981; 441–458
   Google Scholar
• Tidwell Guzman T. G, Vogler W R. The effects of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL-60 and K562. Blood 1981; 57: 794–797
   PubMed Web of Science ®Google Scholar
• Berdel W E, Bausert W RE, Fink U, et al. Anti-tumor action of alkyl-lysophospholipids (Review). Anticancer Res 1981; 1: 345–352
   PubMed Web of Science ®Google Scholar
• Weltzien H U, Munder P G. Synthetic alkyl analogs of lysophosphatidylcholine: Membrane activity, metabolic stability, and effects on immune response and tumor growth. Ether Lipids: Biochemical and Biomedical Aspects, H K Mangold, F Paltauf. Academic Press, New York 1983; 277–308
   Google Scholar
• Runge M H, Andreesen R, Pfleiderer A, et al. Destruction of uman solid tumors by alkyl lysophospholipids. J Natl Cancer Inst 1980; 64: 1301–1306
   PubMed Web of Science ®Google Scholar
• Berger M R, Schmahl D. Modulation of chemical carcinogenesis in rats by alkyl lysophospholipids. Lipids 1987; 22: 935–942
   PubMed Web of Science ®Google Scholar
• Berdel W E, Luz A, Rastetter J, et al. Alkyl-lysophospholipids lack influence on the occurrence of radiation-induced lymphomas and AKR-leukemia. Cancer Lett 1983; 20: 215–221
   PubMed Web of Science ®Google Scholar
• Berdel W E, Schlehe H, Fink U, et al. Early tumor and leukemia response to alkyl-lysophospholipids in a phase I study. Cancer 1982; 50: 2011–2015
   PubMed Web of Science ®Google Scholar
• Herrmann D BJ, Neumann H A, Berdel W E, et al. Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients. Lipids 1987; 22: 962–966
   PubMed Web of Science ®Google Scholar
• Okamoto S, Olson A C, Vogler W R, et al. Purging leukemic cells from simulated human remission marrow with alkyllysophospholipid. Blood 1987; 69: 1381–1387
   PubMed Web of Science ®Google Scholar
• Glasser L, Somberg L B, Vogler W R. Purging murine leukemic marrow with alkyl-phospholipids. Blood 1984; 64: 1288–1291
   PubMed Web of Science ®Google Scholar
• Vogler W R, Somberg L B, Glasser L. Effect of cryopreservation on purging of leukemic marrow with alkyl-lysophospholipids. Exp Hematol 1987; 15: 360–364
   PubMed Web of Science ®Google Scholar
• DiMarco A. Adriamycin (NSC-123127): mode and mechanism of action. Cancer Chemother Rep 1975; 6(Part 3)91–106
   Google Scholar
• Zwelling L A, Kerrigan D, Michaels S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with Adriamycin and 4′-(9-acridinylamino) methanesulfon-m-anisidide. Cancer Res 1982; 42: 2687–2691
   PubMed Web of Science ®Google Scholar
• Siegfried I M, Sartorelli A C, Tritton T R. Evidence for the lack of relationship between inhibition of nucleic acid synthesis and cytotoxicity of Adriamycin. Cancer Biochem Biophys 1983; 6: 137–142
   PubMedGoogle Scholar
• Sengupta S K, Seshadri R, Modest E I, et al. Comparative DNA-binding studies with Adriamycin (ADR), N-trifIuoroacetyladriamycin-14-valerate (AD32), and related compounds (abstr). Proc Am Assoc Cancer Res 1976; 17: 109
   Web of Science ®Google Scholar
• Acton E M. N-alkylation of anthracyclines. Anthracyclines: Current Status and New Developments, S T Crooke, S D Reich. Academic Press, Inc., New York 1980; 15–25
   Google Scholar
• Burke T G, Morin M J, Sartorelli A C, et al. Function of the an-thracycline amino group in cellular transport and cytotoxicity. Mol Pharmacol 1987; 31: 552–556
   PubMed Web of Science ®Google Scholar
• Burke T G, Tritton T R. Location and dynamics of anthracyclines bound to unilamellar phosphatidylcholine vesicles. Biochemistry 1985; 24: 5972–5980
   PubMed Web of Science ®Google Scholar
• Goormaghrigh E, Chatelain P, Caspers J, et al. Evidence of a specific complex between Adriamycin and negatively-charged phospholipids. Biocnim Biophys Acta 1980; 597: 1–14
   PubMed Web of Science ®Google Scholar
• Duarte-Karim M, Ruysschaert J M, Hildebrand J. Affinity of adriamycin to phospholipids A possible explanation for cardiac mitochondrial lesions. Biochim Biophys Res Comm 1976; 71: 658–663
   PubMed Web of Science ®Google Scholar
• Murphree S A, Murphy D, Sartorelli A C, et al. Adriamycin-liposome interactions A magnetic resonance study of the differential effects of cardiolipin on drug-induced fusion and permeability. Biochem Biophys Acta 1982; 691: 97–105
   PubMed Web of Science ®Google Scholar
• Burns C P, North J A, Mossman C J, et al. Fatty acid modification of subcellular organelles of L1210 leukemia cells and lack of effect on doxorubicin (DOXO) localization (abstr). Proc Am Assoc Cancer Res 1988; 29: 10
   Web of Science ®Google Scholar
• Murphree S A, Tritton T R, Smith P L, et al. Adriamycin-induced changes in the surface membrane of sarcoma 180 ascites cells. Biochim Biophys Acta 1981; 649: 317–324
   PubMed Web of Science ®Google Scholar
• Siegfried J A, Kennedy K A, Sartorelli A C, et al. The role of membranes in the mechanism of action of the antineoplastic agent adriamycin: Spin labeling studies with chronically hypoxic and drug resistant tumor cells. J Biol Chem 1983; 258: 339–343
   PubMed Web of Science ®Google Scholar
• Kennedy K A, Siegfried J A, Sartorelli A C, et al. Effects of anthracyclines on oxygenated and hypoxic tumor cells. Cancer Res 1983; 43: 54–59
   PubMed Web of Science ®Google Scholar
• Ramu A, Claubiger O, Magrath I T, et al. Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells. Cancer Res 1983; 43: 5533–5537
   PubMed Web of Science ®Google Scholar
• Ramu A, Glautriger D, Weintraub H. Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells. Cancer Treat Rep 1984; 68: 637–641
   PubMedGoogle Scholar
• Vrignaud P, Montaudon D, Londos-Gagliardi D, et al. Fatty acid composition transport and metabolism in doxorubicin-sensitive and -resistant rat glioblastoma cells. Cancer Res 1986; 46: 3258–3261
   PubMed Web of Science ®Google Scholar
• Tritton T R, Hickman J A. Cell surface membranes as chemotherapeutic target. Experimental and Clinical Progress in Cancer Chemotherapy, F M Muggia. Martinus Nijhoff Publishers, Boston 1985; 81–131
   Google Scholar
• Gosalvez M, Pezzi L, Vivero C. Inhibition of capping of surface immunoglobulins at femtomolar concentrations of adriamycin, compound ICRF-159 and tetrodotoxin. Biochem Soc Trans 1978; 6: 659–661
   PubMedGoogle Scholar
• Crane F L, MacKellar W C, Moore D J, et al. Adriamycin affects plasma membrane redox functions. Biochem Biophys Res Comm 1980; 93: 746–754
   PubMed Web of Science ®Google Scholar
• Sinha B K, Chignell C F. Interaction of antitumor drugs with human erythrocyte ghost membranes and mastocytoma P815:A spin label study. Biochem Biophys Res Comm 1979; 86: 1051–1057
   PubMed Web of Science ®Google Scholar
• Kessel D. Enhanced glycosylation induced by Adriamycin. Mol Pharmacol 1979; 16: 306–312
   PubMed Web of Science ®Google Scholar
• Ohuchi K, Levine L. Adriamycin stimulates canine kidney (MOCK) cells to deacylate cellular lipids and to produce prostaglandins. Prostaglandins and Medicine 1978; 1: 433–439
   PubMedGoogle Scholar
• Zuckier G, Tritton T R. Adriamycin causes up regulation of epidermal growth factor receptors in actively growing cells. Exp Cell Res 1983; 148: 155–161
   PubMed Web of Science ®Google Scholar
• Tokes Z A, Rogers K E, Rembaum A. Synthesis of adriamyuncoupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci (USA) 1982; 79: 2026–2030
   PubMed Web of Science ®Google Scholar
• Tritton T R, Yee G. The anticancer agent Adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248–250
   PubMed Web of Science ®Google Scholar
• Lane P, Vichi P, Bain D L, Tritton T R. Temperature dependence studies of Adriamycin uptake and cytotoxicity. Cancer Res 1987; 47: 4038–4042
   PubMed Web of Science ®Google Scholar
• Furth J J, Cohen S S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinosyladenine. Cancer Res 1968; 28: 2061–2067
   PubMed Web of Science ®Google Scholar
• Kufe D, Spriggs D, Egan E M, et al. Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 1984; 64: 54–58
   PubMed Web of Science ®Google Scholar
• Raetz C RH, Chu M Y, Srivastava S P, et al. Aphospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science 1977; 196: 303–305
   PubMed Web of Science ®Google Scholar
• Ryu E K, Ross R J, Matsushita T, et al. Phospholipid-nucleoside conjugates. 3. Synthesis and preliminary biological evaluation of l-β-D-arabinofuranosylcytosine 5′-monophosphate-L-1,2-dipalmitin and selected 1–0-D-arabinofuranosylcytosine 5′-diphosphate-L-1,2-diacylglycerols. J Med Chem 1982; 25: 1322–1329
   PubMed Web of Science ®Google Scholar
• Hauser G, Eichberg J. Identification of cytidine diphosphate-diglyceride in the pineal gland of the rat and its accumulation in the presence of DL-propranolol. J Biol Chem 1975; 250: 105–112
   PubMed Web of Science ®Google Scholar
• Turcotte J G, Srivastava S P, Steim J M, et al. Cytotoxic liponuclec-tide analogs. U. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety. Biochim Biophys Acta 1980; 619: 619–631
   Google Scholar
• Hong C I, An S, Buchheit D J, et al. 1-β-D-arabinofuranosylcytc-sine-phospholipid conjugates as prodrugs of ara-C. Cancer Drug Delivery 1984; 1: 181–190
   PubMedGoogle Scholar
• Berdel W E, Danhauser S, Schick H D, et al. Antineoplastic activity of conjugates of lipids and l-13-D-arabinofuranosylcytosine. Lipids 1987; 22: 943–946
   PubMed Web of Science ®Google Scholar
• Hong C I, Kirisits A J, Nechaev A, et al. Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols. J Med Chem 1985; 28: 171–177
   PubMed Web of Science ®Google Scholar
• Hong C I, Kirisits A J, Buchheit D J, et al. 1-β-D-arabino-furanosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs. Cancer Drug Delivery 1986; 3: 101–113
   PubMedGoogle Scholar
• Hong C I, An S, Buchheit D J, et al. Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-β-D-arabinoruranosylcytosine conjugates of ether lipids. J Med Chem 1986; 29: 2038–2044
   PubMed Web of Science ®Google Scholar
• Hwang K M, Sartorelli A C. Use of plant lectin-induced agglutination to detect alterations in surface architecture of sarcoma 180 caused by antineoplastic agents. Biochem Pharmacol 1975; 24: 1149–1152
   PubMed Web of Science ®Google Scholar
• Wildenauer D, Weger N. Reactions of the trifunctional nitrogen mustard tris(2-chloroethyl)-amine(HN3) with human erythrocyte membranes in vitro. Biochem Pharmacol 1979; 28: 2761–2769
   PubMed Web of Science ®Google Scholar
• Dilenfeldt M, Gantner G, Harrer M, et al. Interaction of the alkylating antitumor agent 2,3,5-tris(emyleneimino)-benzoquinone with the plasma membrane of Ehrlich ascites tumor cells. Cancer Res 1981; 41: 289–293
   PubMed Web of Science ®Google Scholar
• Baxter M A, Chahwala S B, Hickman J A, et al. The effects of nitrogen mustard (HN2) on activities of the plasma membrane of PC6A mouse plasmacytoma cells. Biochem Pharmacol 1982; 31: 1773–1778
   PubMed Web of Science ®Google Scholar
• Grunicke H, Putzer H, Scheidl F, et al. Inhibition of tumor growth by aklylation of the plasma membrane. Bioscience Rep 1982; 2: 601–604
   PubMed Web of Science ®Google Scholar
• Wildenauer D B, Oehlmann C E. Interaction of cyclophosphamide metabolites with membrane proteins: an in vitro study with rabbit liver microsomes and human red blood cells. Effect of thiols. Biochem Pharmacol 1982; 31: 3535–3541
   PubMed Web of Science ®Google Scholar
• Grunicke H, Doppler W, Hofmann J, et al. Plasma membrane as target of alkylating agents. Adv Enzyme Reg 1985; 24: 247–261
   PubMedGoogle Scholar
• Sun I L, Crane F L. Bleomycin control of transplasma membrane redox activity and proton movement in HeLa cells. Biochem Pharmacol 1985; 34: 617–622
   PubMed Web of Science ®Google Scholar
• Schroeder F, Fontaine R N, Feller D J, et al. Drug-induced surface membrane phospholipid composition in murine fibroblasts. Biochim Biophys Acta 1981; 643: 76–88
   Google Scholar
• Rozengurt E. Early signals in the mitogenic response. Science 1986; 234: 161–166
   PubMed Web of Science ®Google Scholar
• Fico R M, Chen T K, Canellakis E S. Bifunctional intercalaters: Relationship of antitumor activity of diacridines to the cell membrane. Science 1977; 198: 53–56
   PubMed Web of Science ®Google Scholar
• Canellakis E S, Chen T-K. Relationship of biochemical drug effects to their antitumor activity. 1. Diacridines and the cell membrane. Biochem Pharmacol 1979; 28: 1971–1976
   PubMed Web of Science ®Google Scholar
• Ralph R K. On the mechanism of action of 4′[(9-acridinyl)-amino] methanesulphon-m-anisidide. Eur J Cancer 1980; 16: 595–600
   PubMed Web of Science ®Google Scholar
• Kessel D. Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil. Cancer Res 1980; 40: 322–324
   PubMed Web of Science ®Google Scholar
• Lazo J S, Shansky C W, Sartorelli A C. Reduction in cell surface concanavalin A binding and mannose incorporation into glycoproteins of sarcoma 180 by 6-thioguanine. Biochem Pharmacol 1979; 28: 583–588
   PubMed Web of Science ®Google Scholar
• Koehler K A, Hines J, Mansour E G, et al. Comparison of the membrane-related effects of cytarabine and other agents on model membranes. Biochem Pharmacol 1985; 34: 4025–4031
   PubMed Web of Science ®Google Scholar
• Prasad S B, Sodhi A. Effect of cis-dichlorodiammine platinum (IT) on the agglutinability of tumor and normal cells with concanavalin A and wheat germ agglutinin. Chem Biol Int 1981; 36: 355–367
   PubMed Web of Science ®Google Scholar
• Van den Berg E K, Brazy P C, Huang A T, et al. Cisplatin-induced changes in sodium, chloride, and urea transport by the frog skin. Kidney Int 1981; 19: 8–14
   PubMed Web of Science ®Google Scholar
• Scanlon K J, Safirstein R L, Thies H, et al. Inhibition of amino acid transport by cis-diamminedichloroplatinum (II) derivatives in L1210 murine leukemia cells. Cancer Res 1983; 43: 4211–4215
   PubMed Web of Science ®Google Scholar
• Aggarwal S K, Niroomand-Rad I. Effect of cisplatin on the plasma phosphatase activities in ascites sarcoma-180 cells: a cytochemical membrane study. J Histochem Cytochem 1983; 31: 307–317
   PubMed Web of Science ®Google Scholar
• Okada K, Yamada S, Kawashima Y, et al. Ceil injury by antineoplastic agents and influence of coenzyme Q” on cellular potassium activity and potential difference across the membrane in rat liver cells. Cancer Res 1980; 40: 1663–1667
   PubMed Web of Science ®Google Scholar
• Burns C P, Rozengurt E. Extracellular Na+ and initiation of DNA synthesis: Role of intracellular pH and K+. J Cell Biol 1984; 98: 1082–1089
   PubMed Web of Science ®Google Scholar
• Lazo J S. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol 1986; 35: 1919–1923
   PubMed Web of Science ®Google Scholar
• Berdel W E, Schick H D, Fink U, et al. Cytotoxicity of the alkyl-linked lipoidal amine 4-aminomethyl-1-[2,3-(di-n-decyloxy)-n-propyl]-4 phenylpiperdine (CP-46,665) in cells from human tumors and leukemias. Cancer Res 1985; 45: 1206–1213
   PubMed Web of Science ®Google Scholar
• Shqji M, Vogler W R, Kuo J F. Inhibition of phospholipid/Ca2+-dependent protein kinase and phosphorylation of leukemic cell proteins by CP-46,665–1, a novel antineoplastic lipoidal amine. Biochem Biophys Res Commun 1985; 127: 590–595
   PubMed Web of Science ®Google Scholar
• Bernacki R, Porter C, Korytnyk W, et al. Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Reg 1978; 16: 217–237
   Google Scholar
• Bernacki R J, Korytnyk W. Development of membrane sugar and nucleotide sugar analogs as potential inhibitors or modifiers of cellular glycoconjugates. The Gycoconjugates, M I Horowitz. Academic Press, New York 1982; Volume IV: 245–263
   Google Scholar
• Medoff G, Valeriote F, Little J R, . Antitumor effects of amphotericin B. Progress in Cancer Research and Therapy, Vol. 16, Augmenting Agents in Cancer Therapy, E M Hersh, M A Chirigos, M I Mastrangelo, et al. Raven Press, New York 1981; 479–495
   Google Scholar
• Friedman R M. Antiviral activity of interferons. Bacteriol Rev 1977; 41: 543–567
   PubMedGoogle Scholar
• Gresser I, Tovey M G. Antitumor effects of interferon. Biochim Biophys Acta 1978; 516: 231–247
   PubMed Web of Science ®Google Scholar
• Pfeffer L M, Landsberger F R, Tamm I. Beta-interferon-induced time-dependent changes in the plasma membrane lipid bilayer of cultured cells. J Interferon Res 1981; 1: 613–620
   PubMedGoogle Scholar
• Chandrabose K, Cuatrecasas P, Pottathil R. Changes in fatty acyl chains of phospholipids induced by interferon in mouse sarcoma S-180 cells. Biochem Biophys Res Comm 1981; 98: 661–668
   PubMed Web of Science ®Google Scholar
• Pfeffer L M, Wang E, Tamm I. Interferon inhibits the redistribution of cell surface components. J Exp Med 1980; 152: 469–474
   PubMed Web of Science ®Google Scholar
• Chang E H, Jay F T, Friedman R M. Physical, morphological and biochemical alterations in the membrane of AKR mouse cells after interferon treatment. Proc Natal Acad Sci (USA) 1978; 75: 1859–1863
   PubMed Web of Science ®Google Scholar
• Grimley P M, Aszalos A. Early plasma membrane depolarization by alpha interferon: biologic correlation with antiproliferative signal. Biochem Biophys Res Comm 1987; 146: 300–306
   PubMed Web of Science ®Google Scholar
• Knight E, Korant B D. A cell surface alteration in mouse L cells induced by interferon. Biochem Biophys Res Comm 1977; 74: 707–713
   PubMed Web of Science ®Google Scholar
• Burns C P, Spector A A. Membrane fatty acid modification in tumor cells: A potential therapeutic adjunct. Lipid 1987; 22: 178–184
   PubMed Web of Science ®Google Scholar
• Spector A A, Bums C P. Perspectives in cancer research-Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res 1987; 47: 4529–4537
   PubMed Web of Science ®Google Scholar
• Brcnneman D E, Kaduce T, Spector A A. Effect of dietary fat saturation on acylcoenzyme A: cholesterol acyltransferase activity of Ehrlich cell microsomes. J Lipid Res 1977; 18: 582–591
   PubMed Web of Science ®Google Scholar
• Burns C P, North J A, Mossman C J, et al. Modification of the fatty acid composition of L1210 leukemia subcellular organelles. Lipids 1988; 23: 615–618
   PubMed Web of Science ®Google Scholar
• Kaduce T L, Awad A B, Fontenelle L I, et al. Effect of fatty acid saturation on α-aminoisobutyric acid transport in Ehrlich ascites cells. J Biol Chem 1977; 252: 6624–6630
   PubMed Web of Science ®Google Scholar
• Burns C P, Luttenegger D G, Dudley D T, et al. Effect of modification of plasma membrane fatty acid composition on fluidity and methotrexate transport in L1210 murine leukemia cells. Cancer Res 1979; 39: 1726–1732
   PubMed Web of Science ®Google Scholar
• King M E, Spector A A. Effect of specific fatty acyl enrichments on membrane physical properties detected with a spin label probe. J Biol Chem 1978; 253: 6493–6501
   PubMed Web of Science ®Google Scholar
• Gould R J, Ginsberg B H, Spector A A. Lipid effects on the binding properties of a reconstituted insulin receptor. J Biol Chem 1982; 257: 477–484
   PubMed Web of Science ®Google Scholar
• Love J A, Saum W R, McGee R. The effects of exposure to exogenous fatty acids and membrane fatty acid modification on the electrical properties of NG108–15 cells. Cell Mol Neurobiol 1985; 5: 333–352
   PubMed Web of Science ®Google Scholar
• Levine L, Worth N. Eicosapentaenoic acid: Its effects on arachidonic acid metabolism by cells in culture. J Allergy Clin Immunol 1984; 74: 430–436
   PubMed Web of Science ®Google Scholar
• Bums C P, Dudley D T. Temperature dependence and effect of membrane lipid alteration on melphalan transport in L1210 murine leukemia cells. Biochem Pharmacol 1982; 31: 2116–2119
   PubMed Web of Science ®Google Scholar
• Burns C P, North J A. Adriamycin transport and sensitivity in fatty acid-modified leukemic cells. Biochim Biophys Acta 1986; 888: 10–17
   PubMed Web of Science ®Google Scholar
• Burns C P, Luttenegger D G, Spector A A. Effect of dietary fat saturation on survival of mice with L1210 leukemia. J Natl Cancer Inst 1978; 61: 513–515
   PubMed Web of Science ®Google Scholar
• Guffy M M, North J A, Burns C P. Effect of cellular fatty acid alteration on Adriamycin sensitivity in cultured L1210 leukemia cells. Cancer Res 1984; 44: 1863–1866
   PubMed Web of Science ®Google Scholar
• Grundy S M, Ahrens E H, Jr. The effects of unsaturated dietary fats on absorption, excretion, synthesis, and distribution of cholesterol in man. J Clin Invest 1970; 49: 1135–1152
   PubMed Web of Science ®Google Scholar
• Lee T H, Hoover R L, Williams J D, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 312: 1217–1224
   PubMed Web of Science ®Google Scholar
• Burns C P, Rosenberger J A, Luttenegger D G. Selectivity in modification of the fatty acid composition of normal mouse tissues and membranes in vivo. Ann Nutr Metab 1983; 27: 268–277
   PubMed Web of Science ®Google Scholar